Lymphoma & Plasma Cell Disorders
News
Risks of watchful waiting in follicular lymphoma
A subset of follicular lymphoma (FL) patients managed with watchful waiting are vulnerable to organ dysfunction and transformation, according to...
From the Journals
Researchers propose new acute leukemia subtypes
The researchers found genetic similarities between MPAL and other acute leukemias that could help refine treatment options.
Guidelines
Best practices defined for proton therapy in mediastinal lymphomas
The limited availability of proton therapy calls for case selection based on a clear understanding of which cases will derive most benefit from...
News
ASCO addresses financial barriers to cancer clinical trials
The American Society of Clinical Oncology (ASCO) has issued a policy statement addressing financial barriers to patient participation in cancer...
Conference Coverage
STORM trial shows response in penta-refractory myeloma
Selinexor and low-dose dexamethasone produced a “clinically meaningful benefit” in the phase 2 trial.
From the Journals
Be wary of watchful waiting in follicular lymphoma
Management changes may be warranted.
From the Journals
Pruritus linked to wide variety of cancers
The odds of specific cancers vary by race.
News
FDA approves drug for hairy cell leukemia
The U.S.
News
FDA approves new hairy cell leukemia drug
Moxetumomab pasudotox-tdfk (Lumoxiti) is approved to treat adults with relapsed or refractory hairy cell leukemia.
News
New U.S. cancer cases may exceed 2.3 million by 2035
The American Association for Cancer Research (AACR) has released its annual Cancer Progress Report, detailing recent advances in the fight against...
From the Journals
Novel AKT inhibitor active against MM cells
The investigational agent showed multiple myeloma-specific cytotoxicity in human cells, and antimyeloma activity in mouse models.